286 related articles for article (PubMed ID: 12975499)
1. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.
Thorkildsen C; Neve S; Larsen BD; Meier E; Petersen JS
J Pharmacol Exp Ther; 2003 Nov; 307(2):490-6. PubMed ID: 12975499
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
Wang Q; Brubaker PL
Diabetologia; 2002 Sep; 45(9):1263-73. PubMed ID: 12242459
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
5. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
[TBL] [Abstract][Full Text] [Related]
6. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
[TBL] [Abstract][Full Text] [Related]
7. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice.
Fosgerau K; Jessen L; Lind Tolborg J; Østerlund T; Schæffer Larsen K; Rolsted K; Brorson M; Jelsing J; Skovlund Ryge Neerup T
Diabetes Obes Metab; 2013 Jan; 15(1):62-71. PubMed ID: 22862961
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.
Burcelin R; Dolci W; Thorens B
Metabolism; 1999 Feb; 48(2):252-8. PubMed ID: 10024091
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.
Park CW; Kim HW; Ko SH; Lim JH; Ryu GR; Chung HW; Han SW; Shin SJ; Bang BK; Breyer MD; Chang YS
J Am Soc Nephrol; 2007 Apr; 18(4):1227-38. PubMed ID: 17360951
[TBL] [Abstract][Full Text] [Related]
10. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
Green BD; Irwin N; Gault VA; Bailey CJ; O'Harte FP; Flatt PR
J Endocrinol; 2005 May; 185(2):307-17. PubMed ID: 15845923
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
[TBL] [Abstract][Full Text] [Related]
12. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
13. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
Xiao Q; Giguere J; Parisien M; Jeng W; St-Pierre SA; Brubaker PL; Wheeler MB
Biochemistry; 2001 Mar; 40(9):2860-9. PubMed ID: 11258897
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010.
Werner U
Ann Endocrinol (Paris); 2008 Apr; 69(2):164-5. PubMed ID: 18417092
[No Abstract] [Full Text] [Related]
15. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
16. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I
Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
[TBL] [Abstract][Full Text] [Related]
17. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
[TBL] [Abstract][Full Text] [Related]
18. S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors.
Huang P; Meng L; Tan J; Gu X; Huang M; Huang F; Ma R; Wang J
Life Sci; 2021 Apr; 270():119136. PubMed ID: 33508289
[TBL] [Abstract][Full Text] [Related]
19. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.
Gu W; Winters KA; Motani AS; Komorowski R; Zhang Y; Liu Q; Wu X; Rulifson IC; Sivits G; Graham M; Yan H; Wang P; Moore S; Meng T; Lindberg RA; Véniant MM
Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E624-32. PubMed ID: 20647556
[TBL] [Abstract][Full Text] [Related]
20. Effects and molecular mechanisms of the antidiabetic fraction of Acorus calamus L. on GLP-1 expression and secretion in vivo and in vitro.
Liu YX; Si MM; Lu W; Zhang LX; Zhou CX; Deng SL; Wu HS
J Ethnopharmacol; 2015 May; 166():168-75. PubMed ID: 25792018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
